Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etamicastat Multiple Rising Dose in Hypertension
NCT03099226Phase 1Completed
- Sponsor
- BIAL
- Start
- Jul 2008
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of etamicastat in hypertension (HTN) (3 cohorts), sponsored by BIAL. Primary endpoints: Maximum observed plasma concentration at Day 10, Time to reach maximum plasma concentration at Day 10 and 7 more. Started Jul 2008; status: completed.
02
Drugs
etamicastat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03099226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099226.